Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients
- PMID: 3361663
- DOI: 10.1016/s0022-5347(17)42717-0
Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients
Abstract
We evaluated the ability of low doses of botulinum A toxin, an inhibitor of acetylcholine release at the neuromuscular junction, to denervate and relax the spastic rhabdosphincter in 11 men with spinal cord injury and detrusor-sphincter dyssynergia. Toxin concentration, injection volume, percutaneous versus cystoscopic injection of the sphincter and number of injections were evaluated in 3 treatment protocols. All 10 patients evaluated by electromyography after injection showed signs of sphincter denervation. Bulbosphincteric reflexes in the 10 patients evaluated after injection were more difficult to obtain, and they showed a decreased amplitude and normal latency. The urethral pressure profile in the 7 patients in whom it was measured before and after treatment decreased an average of 27 cm. water after toxin injections. Post-void residual urine volume decreased by an average of 146 cc after the toxin injections in 8 patients. In the 8 patients for whom it could be determined toxin effects lasted an average of 50 days. The toxin also decreased autonomic dysreflexia in 5 patients.
Similar articles
-
Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study.Arch Phys Med Rehabil. 1990 Jan;71(1):24-6. Arch Phys Med Rehabil. 1990. PMID: 2297305 Clinical Trial.
-
Botulinum toxin as a new therapy option for voiding disorders: current state of the art.Eur Urol. 2003 Aug;44(2):165-74. doi: 10.1016/s0302-2838(03)00250-1. Eur Urol. 2003. PMID: 12875934 Review.
-
Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients.J Urol. 1996 Mar;155(3):1023-9. doi: 10.1016/s0022-5347(01)66376-6. J Urol. 1996. PMID: 8583552
-
Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin.Arch Phys Med Rehabil. 1998 Jun;79(6):715-7. doi: 10.1016/s0003-9993(98)90050-8. Arch Phys Med Rehabil. 1998. PMID: 9630155 Clinical Trial.
-
[Detrusor-sphincter dyssynergia and botulinum toxin].Ann Readapt Med Phys. 2003 Jul;46(6):319-25. doi: 10.1016/s0168-6054(03)00105-3. Ann Readapt Med Phys. 2003. PMID: 12928137 Review. French.
Cited by
-
Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses.ScientificWorldJournal. 2012;2012:463574. doi: 10.1100/2012/463574. Epub 2012 Sep 10. ScientificWorldJournal. 2012. PMID: 22997495 Free PMC article. Clinical Trial.
-
The management of neurogenic lower urinary tract dysfunction after spinal cord injury.Nat Rev Urol. 2016 Dec;13(12):705-714. doi: 10.1038/nrurol.2016.206. Epub 2016 Oct 25. Nat Rev Urol. 2016. PMID: 27779229 Review.
-
Novel Applications of Non-Invasive Intravesical Botulinum Toxin a Delivery in the Treatment of Functional Bladder Disorders.Toxins (Basel). 2021 May 18;13(5):359. doi: 10.3390/toxins13050359. Toxins (Basel). 2021. PMID: 34069951 Free PMC article. Review.
-
Current and potential urological applications of botulinum toxin A.Nat Rev Urol. 2015 Sep;12(9):519-33. doi: 10.1038/nrurol.2015.193. Epub 2015 Aug 11. Nat Rev Urol. 2015. PMID: 26260879 Review.
-
A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of tension-type headache.Curr Rev Pain. 2000;4(1):31-5. doi: 10.1007/s11916-000-0007-5. Curr Rev Pain. 2000. PMID: 10998713
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical